Header

UZH-Logo

Maintenance Infos

New insights into IL-12-mediated tumor suppression


Tugues, S; Burkhard, S H; Ohs, I; Vrohlings, M; Nussbaum, K; Vom Berg, J; Kulig, P; Becher, B (2015). New insights into IL-12-mediated tumor suppression. Cell Death and Differentiation, 22(2):237-246.

Abstract

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent cytokines in mediating antitumor activity in a variety of preclinical models. Through pleiotropic effects on different immune cells that form the tumor microenvironment, IL-12 establishes a link between innate and adaptive immunity that involves different immune effector cells and cytokines depending on the type of tumor or the affected tissue. The robust antitumor response exerted by IL-12, however, has not yet been successfully translated into the clinics. The majority of clinical trials involving treatment with IL-12 failed to show sustained antitumor responses and were associated to toxic side effects. Here we discuss the therapeutic effects of IL-12 from preclinical to clinical studies, and will highlight promising strategies to take advantage of the antitumor activity of IL-12 while limiting adverse effects.

Abstract

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent cytokines in mediating antitumor activity in a variety of preclinical models. Through pleiotropic effects on different immune cells that form the tumor microenvironment, IL-12 establishes a link between innate and adaptive immunity that involves different immune effector cells and cytokines depending on the type of tumor or the affected tissue. The robust antitumor response exerted by IL-12, however, has not yet been successfully translated into the clinics. The majority of clinical trials involving treatment with IL-12 failed to show sustained antitumor responses and were associated to toxic side effects. Here we discuss the therapeutic effects of IL-12 from preclinical to clinical studies, and will highlight promising strategies to take advantage of the antitumor activity of IL-12 while limiting adverse effects.

Statistics

Citations

39 citations in Web of Science®
36 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Experimental Immunology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:2015
Deposited On:11 Dec 2014 15:25
Last Modified:05 Apr 2016 18:36
Publisher:Nature Publishing Group
ISSN:1350-9047
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1038/cdd.2014.134
PubMed ID:25190142

Download

Full text not available from this repository.
View at publisher